Vitamin D and Cardiovascular Disease: The Final Chapter? by Purow, Jeremy I. & Sokol, Seth I.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Vitamin D and Cardiovascular 
Disease: The Final Chapter?
Jeremy I. Purow and Seth I. Sokol
Abstract
Vitamin D deficiency is globally prevalent and has been associated with the 
pathogenesis and complications of cardiovascular disease (CVD) and its risk fac-
tors. Defining these relationships has been challenging, and the clinical applications 
of vitamin D screening and supplementation for CVD risk prevention and modi-
fication have only recently become clearer. Most of the available evidence includes 
large observational studies and smaller randomized trials that scarcely evaluate CV 
outcomes as primary endpoints. Additionally, these studies include methodological 
inconsistencies, making it difficult to ascertain the benefits of vitamin D supple-
mentation. However, more recently, randomized trials have been conducted which 
utilize CVD outcomes as primary endpoints, while assessing the effects of high dose 
vitamin D supplementation on CV health. Despite observational evidence as well 
as a conventional consensus that vitamin D supplementation improves CV health, 
these studies suggest that vitamin D supplementation likely has no benefit in this 
regard, at least in the follow-up period and populations evaluated.
Keywords: vitamin D deficiency, cardiovascular disease, endothelial function, 
hypertension, heart failure, renal disease, prevention, vitamin D
1. Introduction
Cardiovascular disease (CVD) is the most common cause of death in the devel-
oped world and is forecasted to be the leading cause of death and morbidity in 
developing countries by 2020 [1]. According to the American Heart Association, 
9.0% (24.3 million in 2016) of adults (≥20 years of age) in the United States live 
with CVD (including coronary heart disease, heart failure, and stroke). This num-
ber increases to 48.0% when including hypertension [2]. CVD is a multifactorial 
disease that includes a complex interplay between genetics, environmental factors, 
and risk factors.
Despite effective measures for control and modification of traditional risk 
factors, a significant amount of risk remains. Therefore, the identification of 
easily modifiable novel risk factors has been heavily investigated over the past few 
decades.
In addition to the well-known relationship between vitamin D and bone health, 
there has been considerable interest of the possible linkage between vitamin D and 
CV health due to the expression of the vitamin D receptor (VDR) on cardiomyo-
cytes and vascular cells [3, 4]. Vitamin D plays an extensive role in the regulation of 
numerous pathways implicated in CVD pathogenesis. Interestingly, various studies 
note that CVD events are higher in the winter months, a time when vitamin D 
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levels are known to be at their lowest due to lack of sunlight [5, 6]. A similar trend 
is noted in certain populations with poor cutaneous vitamin D production, such as 
African Americans, who are more prone to developing hypertension and CV disease 
[6]. Lastly, low vitamin D levels (<20 ng/mL) have been independently linked to 
increased morbidity and mortality [7, 8]. Although convincing, this evidence does 
not demonstrate causality, but supports a hypothesis for further study.
Prior to 2017, randomized controlled trials had mostly relied on surrogate 
or secondary endpoints for CV risk reduction. Study methodologies have been 
heterogeneous, and results have often been conflicting. In the absence of results 
from these trials, regular supplementation has not been recommended for CV risk 
modulation. Despite the lack of recommendations, use of vitamin D supplements 
for this purpose had risen dramatically.
However, more recent trials have been conducted that have assessed CV risk 
reduction as a primary endpoint. These trials have given researchers and clinicians 
a better understanding of the effects of vitamin D supplementation and whether it 
should be indicated to reduce the risk of developing CVD [9, 10].
The following chapter will discuss the prevalence of vitamin D deficiency, 
describe vitamin D synthesis and metabolism, and provide an overview on the 
biologic plausibility and current state of the evidence linking vitamin D to CV 
health and disease.
2. Vitamin D deficiency
Vitamin D deficiency is found in 30–50% of the general population, and preva-
lence estimates suggest that more than 1 billion people worldwide are vitamin D 
insufficient or deficient [4, 11].
Vitamin D deficiency is indicated by serum levels of 25(OH)D < 20 ng/mL [4]. 
Serum levels >30 ng/mL are likely optimal for bone health, but some studies have 
shown benefits with lesser values. Parathyroid hormone (PTH) suppression appears 
to plateau at levels between 30 and 40 ng/mL [12]. There has been no agreement 
on optimum 25(OH)D levels required for purported health benefits beyond skel-
etal health. One study suggested that 25(OH)D levels below 11–14 ng/mL signify 
increased CVD risk [13]. Levels in the range of 21–29 ng/mL are considered by some 
as insufficient, a definition that would label the majority of the U.S. population 
vitamin D insufficient [4].
The Endocrine Society does not recommend screening for vitamin D deficiency 
in individuals who are not at risk for it [12]. Many of the risk factors for vitamin 
D deficiency have been identified. Some of these include inadequate cutaneous 
synthesis stemming from insufficient sun exposure or dark skin pigmentation and 
inadequate dietary intake. Other noted risk factors include aging, obesity, renal 
disease, liver disease, disorders that affect fat absorption (e.g. celiac disease, inflam-
matory bowel diseases, types of bariatric surgery), increased catabolism due to 
medications (e.g. steroids, anticonvulsants etc.), and other hereditable (e.g. rickets) 
and acquired disorders (e.g. hyperthyroidism) [4].
3. Vitamin D metabolism
Vitamin D’s active form, 1a,25-dihydroxyvitamin D (1,25[OH]2D3) plays a criti-
cal role in influencing a myriad of metabolic pathways [14].
Natural sunlight exposure contributes to more than 90% of vitamin D 
(D3-cholecalciferol) production in humans [15]. UV-B irradiation absorbed by skin 
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keratinocytes triggers photolysis of 7-dehydrocholesterol (pro-vitamin D3) in the 
plasma membrane, which is then swiftly modified into vitamin D3 by heat [4, 16].
Dietary supply of vitamin D (D2-ergocalciferol) contributes to the remainder 
of the total amount of vitamin D in the body. Foods containing vitamin D include 
oily fish (salmon, sardines, and mackerel), cod liver oil, egg yolk, mushrooms, and 
fortified milk, orange juice, cereals, and cheese [11, 12].
D3 and D2 from the skin and diet, respectively, each undergo two sequential 
hydroxylation’s: 25-hydroxylation in the liver and then 1,25-dihydroxylation in the kid-
ney. In order to assess vitamin D status from oral intake and endogenous production, 
the primary metabolite of vitamin D, 25(OH)D, should be measured [11, 15, 17]. The 
hydroxylation of 25(OH)D to its biologically active form, 1,25(OH)2D3, is controlled 
by PTH [11, 18].
Most of the known biological effects of 1,25(OH)2D3 are mediated through the 
vitamin D3 receptor (VDR), part of the superfamily of nuclear hormone receptors, 
which mediates transcriptional gene regulation [19].
Over 200 genes are regulated by 1,25(OH)2D3. These include genes directly or 
indirectly responsible for renin and insulin production, anti-inflammatory cytokine 
release, proinflammatory cytokine suppression, and regulation of vascular smooth 
muscle cell (VSMC) and cardiomyocyte proliferation [11, 20].
1,25(OH)2D3 is also involved in non-genomic mediated intracellular signal-
ing, demonstrating immunomodulatory, antiproliferative, and pro-differentiative 
activities in experimental settings [19].
4. Biologic plausibility
Characterizing vitamin D deficiency as a primary risk factor for CVD is chal-
lenging due to the multitude of complex interacting pathways involving vitamin 
D. The vitamin D receptor is nearly ubiquitous in human cells including vascular 
smooth muscle cells (VSMC), endothelial cells, cardiac myocytes, juxtaglomeru-
lar, and most immune cells, all implicated in the pathogenesis and progression of 
CVD [11, 18].
Immune cells such as activated CD4+ and CD8+ T cells, B cells, neutrophils, 
macrophages, and dendritic cells are capable of converting 25OHD3 into 1,25OHD3, 
its active form. Moreover, 1,25 hydroxylase, the rate-limiting enzyme in this 
pathway, is present in activated macrophages [21–23]. Lastly, VSMC and endothelial 
cells also express 1,25 hydroxylase, suggesting that these cells have an autocrine 
mechanism allowing them to modulate the effects of vitamin D on the vasculature 
[24, 25].
Vitamin D has various direct and indirect effects on CV function. 1,25(OH)2D3 
directly modulates VSMC and expression of vascular endothelial growth factor via 
the VDR and CYP27B1 expression in VSMC’s and endothelial cells. 1,25(OH)2D3 
has an inhibitory effect on hypertrophy and proliferation of VSMC in vitro and 
in cultured cardiac myocytes. It also plays an important role in inflammation and 
thrombosis [21, 24]. In a swine model of atherosclerosis, vitamin D deficiency 
accelerated plaque progression by enhancing inflammation in epicardial adipose tis-
sue [26]. Inverse associations between vitamin D deficiency and thrombogenicity, 
vascular inflammation, and vascular calcification have been demonstrated [27–29].
Indirectly, the expression of renin in vivo is strongly regulated by vitamin D, 
and an inverse relationship between vitamin D levels and renin expression has been 
demonstrated experimentally [30–32]. 1,25(OH)2D3 binds to the renin promoter 
region and inhibits renin transcription [30]. VDR knockout mice were shown to 
have increased levels of renin and angiotensin II and, therefore, a higher prevalence 
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of hypertension [32]. Thus, vitamin D is implicated in blood pressure regulation 
and myocardial thickening.
Another indirect effect of vitamin D on CVD is the regulation of matrix metal-
loproteinase 2 and 9 production. Increased metalloproteinases have been associated 
with cardiac fibrosis, hypertrophy and heart failure in mice [33, 34].
Vitamin D deficiency may also indirectly harm the CV system by inducing 
hyperparathyroidism, which may act upon parathyroid hormone (PTH) receptors 
within the blood vessel wall and the myocardium [35]. Multiple studies have been 
able to demonstrate an association between elevated PTH levels and hypertension, 
cardiac dysfunction and vascular disease [35, 36].
Lastly, hyperlipidemia has also been associated with vitamin D deficiency. This 
is likely a result of decreased transcriptional activity of the VDR, leading to the 
increase of hepatic cholesterol production [37].
5. The clinical evidence
Vitamin D deficiency is prevalent in CVD patients [11]. Most studies showing 
an association between inadequate 25OHD3 and poor outcomes in CV health are 
observational, hindering the establishment of a causal relationship. Furthermore, 
significant differences across studies hamper the ability to make valid and con-
sistent conclusions. These differences include varying definitions of vitamin D 
deficiency and lack of seasonal adjustment and properly defined CV outcomes. 
Further difficulties include the use of single baseline measurements of vitamin 
D (which may be an inaccurate assessment of overall vitamin D status), a poor 
understanding of the role of high PTH on CVD, and the use of other disease 
modulating drugs such as calcium and statins in active and placebo groups, which 
may affect study results.
However, newer studies implement clearly defined primary endpoints, differing 
frequencies of vitamin D supplementation, and a diverse cohort of participants. 
These studies allow for a clearer understanding of the effects of vitamin D supple-
mentation on CVD health.
6. Observational data
Several large-scale observational studies have been completed over the past 
decades. The NHANES III national cohort registry found a significant inverse 
relationship between 25(OH)D levels and all-cause mortality, but a non-significant 
association between 25(OH)D levels and CVD mortality [8].
In the Intermountain Heart Collaborative Study Group, significantly higher 
rates of diabetes, hyperten sion, hyperlipidemia, and peripheral vascular disease 
were found in those with serum 25(OH)D levels below 30 ng/mL. Additionally, 
low serum 25(OH)D levels were also linked to coronary artery disease, myocardial 
infarction (MI), heart failure, stroke and incident death [38].
In the Health Professionals Follow-up Study, men deficient in 25(OH)D (≤15 ng/
mL) had a higher risk of MI than men with sufficient levels (≥30 ng/mL) [39].
In contrast, other prospective studies have had discordant results. In the 
MIDSPAN family study, with a median follow up of 14.4 years, plasma levels of 
25OHD less than 15 ng/mL were associated with all-cause mortality, but not the risk 
of CV diseases [40].
Similiarly, in the MrOS Sleep Study, no relationship between circulating 25(OH)
D levels and risk of CVD events was found [41].
5Vitamin D and Cardiovascular Disease: The Final Chapter?
DOI: http://dx.doi.org/10.5772/intechopen.90106
Additionally, in a study involving 746 patients undergoing coronary angiogra-
phy, no correlation was found between vitamin D levels (<20 ng/mL vs. >20 ng/mL) 
and the degree and severity of coronary artery disease [42].
7. Randomized controlled trials
Prior to 2017, most randomized interventional studies have assessed surrogate 
endpoints rather than hard CV outcomes. In the available studies, there has been 
considerable variation in defining baseline vitamin D status, assessing adequate 
vitamin D dosage, and ascertaining study outcomes.
In a double-blind, placebo controlled, randomized trial where elderly partici-
pants in the United Kingdom received vitamin D3 supplements of 100,000 IU every 
4 months for 5 years, no benefits on CVD outcomes were shown [43].
Additionally, in a systematic review of 18 randomized trials studying the 
efficacy of supplementation with vitamin D (with or without calcium) on various 
cardiometabolic outcomes, only four reported on incident CVD. There were no 
significant reductions in CVD risk found in these trials [44].
Postmenopausal women in the Women’s Health Initiative (WHI) receiving 
calcium carbonate (1000 mg/day) and vitamin D (400 IU/day) had no reduc-
tion in their risk of coronary events or stroke during the 7 year follow-up period. 
Treatment with calcium and vitamin D also had no effect on blood pressure reduc-
tion, hypertension development and coronary artery calcification. In the overall 
participant cohort, supplementation did not reduce the overall incidence of heart 
failure, yet some benefits were noted in participants considered to be at low risk for 
heart failure. Lastly, in a follow-up 4.9 years after the culmination of the study, no 
positive effects on CVD were found [45–49].
More recent studies on vitamin D supplementation have made use of well-
defined CV outcomes as primary endpoints. In 2017, the results of the Vitamin D 
Assessment study (VIDA), a randomized, double blinded, placebo-controlled study 
on the effects of high-dose, monthly vitamin D supplementation in the general 
population aged 50–84, were published. 5,110 patients were randomized to receive 
either an initial oral vitamin D dose of 200,000 IU followed by 100,000 IU monthly 
or placebo. Primary outcomes included incident CVD and death. Secondary out-
comes included MI, angina, heart failure, hypertension, arrhythmias, chronic isch-
emic heart disease, arteriosclerosis, stroke, and venous thrombosis. Additionally, 
pre-specified subgroup analysis for the primary endpoint was done for patients 
with vitamin D deficiency (<20 ng/mL) and established CVD. Results of the study 
showed that high doses of monthly vitamin D supplementation provided no benefit 
to CV health over placebo. However, the study is limited by a low event rate and 
decreased power, especially for subgroup analysis in those deficient at baseline. 
Supplementation was monthly, leaving the question of whether daily dosing may be 
better. Finally, the funding of the clinical trial only allowed for a median follow-up 
time of 3.3 years and, therefore, the long-term effects of high dose, monthly vitamin 
D supplementation remain in question [10].
Another recent placebo-controlled trial, known as the VITAL study, assessed the 
effects of more frequent vitamin D supplementation (2,000 IU of vitamin D and 
1 g of omega-3 per day) on CVD and cancer. The primary endpoint in the CV arm 
was major CV events, which included MI, stroke, and cardiac related death. 25,871 
subjects participated in the study and the median follow-up time was 5.3 years. The 
trial found that daily vitamin D supplementation had no benefit on CV health. The 
strengths of the study included daily vitamin D supplementation, longer follow-up 
times, and participant diversity [9].
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A recent updated meta-analysis, including VITAL and VIDA, with a total of 
83,291 patients, indicated that vitamin D supplementation had no benefit on CV 
health. Only 4 of the 21 trials used CVD as a primary endpoint. It has also been 
shown that vitamin D supplementation provided no benefit toward the secondary 
endpoints of MI, stroke, CVD mortality, and all-cause mortality [50]. This meta-
analysis, though, lacks complete and specific patient level data and, therefore, 
subgroup analysis is difficult.
8. Hypertension
Low vitamin D status has been heavily linked to an increased prevalence of 
hypertension. A prospective examination of 1,211 non-hypertensive men, over a 
15 year follow-up period, demonstrated an inverse association between vitamin D 
levels and hypertension development [51].
In addition to the demonstrated link between low vitamin D levels and hyper-
tension development, the Framingham Offspring Study suggested that low vitamin 
D levels may also increase the risk associated with already existing hypertension, 
which may substantially augment the risk of future CV events [52].
Contrary to observational evidence, randomized controlled trials of vitamin 
D repletion have not shown significant changes in blood pressure in vitamin D 
deficient individuals with prehypertension or hypertension [53, 54].
In a randomized, double blind trial involving 283 black subjects given either pla-
cebo, 1,000, 2,000, or 4,000 IU/day of vitamin D for 3 months, significant modest 
reductions in systolic blood pressure were seen. Systolic blood pressure decreased 
by 0.2 mmHg for every 1 ng/mL increase in vitamin D, but no effect on diastolic 
pressure was demonstrated [55].
In VITdish, another small (N = 159) randomized, double-blind, placebo-con-
trolled trial, there was no effect of vitamin D supplementation on blood pressure 
or other markers of vascular health in older adults with systolic hypertension [56].
A 6 month study of vitamin D3 supplementation including patients with 
resistant hypertension showed similar results. Effects on left ventricular hyper-
trophy were also negligible, although the short follow-up may have limited this 
assessment [57].
In the VIDA study, with monthly high dose vitamin D supplementation, there 
were no significant differences between the vitamin D and placebo groups regard-
ing incident hypertension [10].
Lastly and likewise, in the VITAL study using high daily doses of vitamin D, 
hypertension incidence was not significantly different in the vitamin D and placebo 
groups [9].
9. Endothelial dysfunction
Vitamin D deficiency has been associated with endothelial dysfunction. A 
study involving 23 asymptomatic subjects demonstrated impaired brachial artery 
flow-mediated dilatation (FMD) in subjects with significant vitamin D deficiency. 
Improvement was seen with vitamin D repletion [58].
In contrast, there was no improvement in endothelial-dependent vasodilation 
with active treatment (ergocalciferol 50,000 IU/week) versus placebo in an 8 week 
trial in non-hypertensive, overweight, vitamin D deficient individuals [59].
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Similarly, a prospective placebo-controlled pilot study evaluated the effects of 
vitamin D repletion on endothelial function and inflammation in subjects with both 
vitamin D deficiency and coronary artery disease. The study was conducted over a 
12-week period in 90 subjects. No significant differences between the groups were 
found in reactive hyperemia index (using RH-PAT), blood pressure, and levels of 
hs-CRP, IL-6, IL-12, interferon gamma (INF-gamma), and CXCL-10 [60].
Additionally, in the Prospective Study of the Vasculature in Uppsala Seniors 
(PIVUS) (N = 852), vitamin D levels were positively related to endothelial-indepen-
dent vasodilation in women only. There were no significant relationships between 
vitamin D levels and indices of endothelium-dependent vasodilatation in both men 
and women [61].
Lastly, a recent systematic review including 31 trials and individual-level meta-
analysis (2,571 patients) assessed the relationship between vitamin D and various 
markers of vascular function. The analysis found that most vascular markers 
studied were not significantly effected by vitamin D supplementation [62].
10. Heart failure
The impact of vitamin D supplementation on patients with heart failure has not 
been the focus of large randomized trials.
The RECORD trial (Randomized Evaluation of Calcium Or vitamin D) was a 
trial designed for the secondary prevention of fractures in 5292 participants aged 
≥70 years (conducted between 1999 and 2002). Subjects received oral vitamin D3 
(800 IU/d) plus calcium (1,000 mg calcium carbonate/d), vitamin D3 alone, cal-
cium alone, or a placebo. An analysis of unpublished data from the trial, suggested 
that vitamin D supplementation may decrease heart failure events in the elderly. 
The trial had pre-specified CV endpoints of time to first cardiac failure, time to first 
MI, time to first stroke, and time to first composite outcome of cardiac failure, MI, 
or stroke. The trial, though, was not designed as a CV outcomes trial, and outcomes 
were not subject to an adjudication committee nor verified against medical records. 
Furthermore, significance for heart failure event reduction was reached only when 
off-trial data were used [63].
Several small placebo-controlled studies have been conducted to analyze the 
effects of vitamin D supplementation on differing endpoints in patients with heart 
failure. Results have been conflicting.
In a small randomized, double-blind, placebo-controlled trial (N = 105) in older 
adults with vitamin D deficiency (25-vitamin D < 20 ng/mL) and systolic heart 
failure, subjects were given 100,000 IU of oral vitamin D2 or placebo at baseline 
and 10 weeks. Functional outcomes, quality of life and biomarkers (B-type natri-
uretic peptide (BNP) and tumor necrosis factor (TNF alpha)) were measured at 
baseline, 10 and 20 weeks. BNP was significantly reduced in the active treatment 
group versus placebo, but TNF alpha was not. Despite reduced BNP levels, physical 
function, as measured by the 6-minute walk test and the timed get up and go test, 
did not improve. There was also no change in the Functional Limitations Profile 
measure in the active versus placebo group. A small, but significant worsening in 
quality of life with active treatment was noted, despite a non-significant increase in 
activity level, suggesting a chance finding [64].
Schleithoff et al. examined cytokine profiles with vitamin D3 supplementation in 
younger patients with heart failure. A dose of 2,000 IU per day reduced the pro-
inflammatory marker TNF-alpha levels and increased the anti-inflammatory cyto-
kine interleukin-10 levels, but no significant effects on BNP levels were seen [20].
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A recent randomized, controlled trial assessed the effects of 50,000 IU of 
weekly vitamin D or placebo for 6 months on various measures of physical perfor-
mance (primary endpoint: peak VO2; secondary endpoints: 6-Minute Walk test, 
timed get up and go test, isokinetic muscle strength) in patients with heart failure. 
The study failed to demonstrate any benefits, despite considerable increases in 
serum 25(OH)D levels in the active treatment group [65].
In VINDICATE, a double-blind, randomized, placebo-controlled trial, subjects 
with systolic dysfunction (ejection fraction (EF) ≤ 45%) and vitamin D deficiency 
(<20 ng/mL) were randomized to 4,000 IU of vitamin D3 or placebo. At 12 months, 
there was no significant difference in 6-minute walking distance (primary end-
point), but there was significant improvement in left ventricular (LV) systolic 
function and a reduction in LV end diastolic and end systolic diameter with active 
supplementation [66].
In the EVITA trial, 400 patients with heart failure were randomized to receive 
4,000 IU of vitamin D or placebo daily for 3 years. There was no benefit of supple-
mentation on the primary endpoint of all-cause mortality. Additionally, secondary 
endpoint analysis suggested that vitamin D supplementation was associated with an 
increased frequency of implantation of mechanical circulatory support [67].
11. Renal disease
Observational studies show that there are potential benefits to vitamin D 
supplementation in patients with chronic kidney disease (CKD). In a meta-analysis 
of some of these studies, it was determined that receiving treatment with any 
vitamin D derivative reduces all-cause mortality as well as CV mortality [68]. In 
another, more recent, meta-analysis of observational studies, it has been shown that 
vitamin D treatment may pose benefits toward reducing all-cause mortality and CV 
related mortality [69].
To further assess some of the available randomized, clinical trials for renal 
patients, a meta-analysis was done to test the efficacy of vitamin D supplementa-
tion in these patients. The 13 trials used for the meta-analysis showed no significant 
benefits for serious adverse CV events, all-cause mortality, or CV related mortality 
in CKD patients who supplemented with vitamin D. Unfortunately, there is a lack 
of patient level data relating to patients with CKD, making it difficult to draw any 
conclusions regarding the effects of vitamin D supplementation on CV health in 
this population [70].
In many of the previous studies in patients with CKD, the dosage of vitamin 
D has been limited in order to protect patients from developing hypercalcemia. 
Additionally, a lack of standardization in vitamin D formulations has made it 
especially difficult to compare results in different trials. Larger randomized tri-
als with well-defined primary outcomes need to be conducted in order to further 
define vitamin D’s effect on CVD in renal patients. In 2025, the SIMPLIFIED trial 
is expected to conclude and expectantly give insight into the effects of vitamin D 
supplementation on hard endpoints of all-cause mortality and CV related mortality 
in CKD patients [71, 72].
12. Conclusions
Epidemiologic, observational and laboratory evidence have implicated vitamin 
D deficiency in the pathogenesis and complications of CVD. This lent extensive 
biologic plausibility to the theory that vitamin D levels would be an effective target 
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for CVD prevention. However, like many other trials of vitamin supplementation, 
large randomized placebo-controlled trial data from the general population have 
refuted this theory. Therefore, vitamin D supplementation for the purpose of CVD 
prevention is not recommended for the general public.
13. Future directions
Based on the findings in the most recent clinical trials, it appears that the last 
chapter may have been written regarding the role of vitamin D for CVD prevention 
in the general population. However, many questions still remain and will likely 
fuel ongoing investigation and debate. Was the follow-up in these recent trials 
long enough? Do large trials randomizing by baseline vitamin D status need to be 
conducted since the mean vitamin D levels in VITAL and VIDA were both above the 
deficient threshold of 20 ng/mL? [9, 10]. Are there benefits to vitamin D repletion 
for heart failure outcomes? What is the true benefit of vitamin D repletion on CVD 
outcomes in the chronic kidney disease and dialysis population? These questions 
and others regarding both CVD and other chronic disease states will likely keep the 
book open on vitamin D for the foreseeable future.
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